Filing Details
- Accession Number:
- 0001127602-12-009009
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-03-01 18:16:29
- Reporting Period:
- 2012-02-28
- Filing Date:
- 2012-03-01
- Accepted Time:
- 2012-03-01 18:16:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1097264 | Allos Therapeutics Inc | ALTH | Pharmaceutical Preparations (2834) | 541655029 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1237532 | Jr K Bruce Bennett | 11080 Circlepoint Road Suite 200 Westminster CO 80020 | Vp, Pharmaceutical Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-02-28 | 43,862 | $0.00 | 153,434 | No | 4 | A | Direct | |
Common Stock | Disposition | 2012-02-29 | 3,031 | $1.53 | 150,403 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-03-01 | 3,025 | $1.50 | 147,378 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Represents shares of common stock issued as restricted stock units ("RSUs") awarded under the Company's 2008 Equity Incentive Plan (the "Plan"). The RSUs shall vest in a series of eight (8) successive equal semi-annual installments over the four (4)-year period measured from March 18, 2012 (the "Vesting Commencement Date"), subject to Participant's Continuous Service through each such date.
- These shares are being sold pursuant to a 10b5-1 plan for Mr. Bennett under which a portion of his holdings were sold for tax and estate planning purposes in connection with the delivery of shares covered by restricted stock units which vested on February 28, 2012.
- The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $1.52 to $1.54. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
- The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $1.49 to $1.50. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.